Active surveillance for low-risk prostate cancer worldwide: The PRIAS study

European Urology

Volumn 63, Issue 4, 2013, Pages 597-603

  Bul, Meelan ^a   Zhu, Xiaoye ^a   Valdagni, Riccardo ^b   Pickles, Tom ^c   Kakehi, Yoshiyuki ^d   Rannikko, Antti ^e   Bjartell, Anders ^f   Van Der Schoot, Deric K ^g   Cornel, Erik B ^h   Conti, Giario N ⁱ   Boevé, Egbert R ^j   Staerman, Frédéric ^k   Vis Maters, Jenneke J ^l   Vergunst, Henk ^m   Jaspars, Joris J ⁿ   Strölin, Petra ^o   Van Muilekom, Erik ^p   Schröder, Fritz H ^a   Bangma, Chris H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d KAGAWA UNIVERSITY   (Japan)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g AMPHIA HOSPITAL   (Netherlands)

^h Ziekenhuis Groep Twente   (Netherlands)

ⁱ SANT ANNA HOSPITAL   (Italy)

^j SINT FRANCISCUS GASTHUIS   (Netherlands)

^k Polyclinique les Bleuets ^*  (France)

^l ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^m CANISIUS WILHELMINA HOSPITAL   (Netherlands)

ⁿ Admiraal de Ruyter Ziekenhuis   (Netherlands)

^o Martini Klinik   (Germany)

^p NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

Active surveillance; Prognostic factors; Prostate specific antigen; Prostatic neoplasms; Reclassification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; ACTIVE THERAPY FREE SURVIVAL; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; REGRESSION ANALYSIS;

AGED; DISEASE-FREE SURVIVAL; EPIDEMIOLOGICAL MONITORING; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RISK; SURVIVAL RATE;

EID: 84874546786     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.005     Document Type: Article

References (30)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. F.H. Schroder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
3. M.J. Roobol, M. Kerkhof, and F.H. Schroder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
4. H.G. Welch, and W.C. Black Overdiagnosis in cancer J Natl Cancer Inst 102 2010 605 613
5. R.C. van den Bergh, H. Vasarainen, and H.G. van der Poel Short-term outcomes of the prospective multicentre "Prostate Cancer Research International: Active Surveillance" study BJU Int 105 2010 956 962
6. M. Bul, X. Zhu, and A. Rannikko Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study Eur Urol 62 2012 195 200
7. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
8. N.J. van As, A.R. Norman, and K. Thomas Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297 1305
9. J.J. Tosoian, B.J. Trock, and P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
10. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670
11. M.S. Soloway, C.T. Soloway, A. Eldefrawy, K. Acosta, B. Kava, and M. Manoharan Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831 835
12. J.H. Hayes, D.A. Ollendorf, and S.D. Pearson Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis JAMA 304 2010 2373 2380
13. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
14. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
15. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228 234
16. T.A. Stamey, F.S. Freiha, J.E. McNeal, E.A. Redwine, A.S. Whittemore, and H.P. Schmid Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer Cancer 71 1993 933 938
17. J.I. Epstein, P.C. Walsh, M. Carmichael, and C.B. Brendler Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
18. S.P. Porten, M.R. Cooperberg, and P.R. Carroll The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease BJU Int 105 2010 472 475
19. T. Wolters, M.J. Roobol, and P.J. van Leeuwen Should pathologists routinely report prostate tumour volume? the prognostic value of tumour volume in prostate cancer Eur Urol 57 2010 821 829
20. T. Wolters, M.J. Roobol, and P.J. van Leeuwen A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial J Urol 185 2011 121 125
21. M. Bul, R.C. van den Bergh, and A. Rannikko Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program Eur Urol 61 2012 370 377
22. E.D. Crawford Understanding the epidemiology, natural history, and key pathways involved in prostate cancer Urology 73 2009 S4 S10
23. A.F. Kotb, S. Tanguay, M.A. Luz, W. Kassouf, and A.G. Aprikian Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance Prostate Cancer Prostatic Dis 14 2011 53 57
24. R. Venkitaraman, A. Norman, and R. Woode-Amissah Predictors of histological disease progression in untreated, localized prostate cancer J Urol 178 2007 833 837
25. I.F. San Francisco, L. Werner, M.M. Regan, M.B. Garnick, G. Bubley, and W.C. DeWolf Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance J Urol 185 2011 471 476
26. P.J. Bastian, L.A. Mangold, J.I. Epstein, and A.W. Partin Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis Cancer 101 2004 2001 2005
27. H. Augustin, P.G. Hammerer, and M. Graefen Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction Eur Urol 43 2003 455 460
28. A. Briganti, F.K. Chun, and N. Suardi Prostate volume and adverse prostate cancer features: fact not artifact Eur J Cancer 43 2007 2669 2677
29. S.J. Freedland, W.B. Isaacs, and E.A. Platz Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study J Clin Oncol 23 2005 7546 7554
30. J.J. Liu, J.D. Brooks, M. Ferrari, R. Nolley, and J.C. Presti Jr. Small prostate size and high grade disease - biology or artifact? J Urol 185 2011 2108 2111